Expert Opinion on Therapeutic Targets最新文献_第9页

Kv1.3 in the spotlight for treating immune diseases. Kv1.3 成为治疗免疫疾病的焦点。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.1080/14728222.2024.2315021

María Navarro-Pérez, Jesusa Capera, Anna Benavente-Garcia, Silvia Cassinelli, Magalí Colomer-Molera, Antonio Felipe

{"title":"Kv1.3 in the spotlight for treating immune diseases.","authors":"María Navarro-Pérez, Jesusa Capera, Anna Benavente-Garcia, Silvia Cassinelli, Magalí Colomer-Molera, Antonio Felipe","doi":"10.1080/14728222.2024.2315021","DOIUrl":"10.1080/14728222.2024.2315021","url":null,"abstract":"Introduction: Kv1.3 is the main voltage-gated potassium channel of leukocytes from both the innate and adaptive immune systems. Channel function is required for common processes such as Ca2+ signaling but also for cell-specific events. In this context, alterations in Kv1.3 are associated with multiple immune disorders. Excessive channel activity correlates with numerous autoimmune diseases, while reduced currents result in increased cancer prevalence and immunodeficiencies.Areas covered: This review offers a general view of the role of Kv1.3 in every type of leukocyte. Moreover, diseases stemming from dysregulations of the channel are detailed, as well as current advances in their therapeutic research.Expert opinion: Kv1.3 arises as a potential immune target in a variety of diseases. Several lines of research focused on channel modulation have yielded positive results. However, among the great variety of specific channel blockers, only one has reached clinical trials. Future investigations should focus on developing simpler administration routes for channel inhibitors to facilitate their entrance into clinical trials. Prospective Kv1.3-based treatments will ensure powerful therapies while minimizing undesired side effects.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"67-82"},"PeriodicalIF":5.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Powering down the mitochondrial LonP1 protease: a novel strategy for anticancer therapeutics. 抑制线粒体 LonP1 蛋白酶：抗癌疗法的新策略。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-01-01 Epub Date: 2023-12-29 DOI: 10.1080/14728222.2023.2298358

Rahul Shetty, Roberto Noland, Ghata Nandi, Carolyn K Suzuki

{"title":"Powering down the mitochondrial LonP1 protease: a novel strategy for anticancer therapeutics.","authors":"Rahul Shetty, Roberto Noland, Ghata Nandi, Carolyn K Suzuki","doi":"10.1080/14728222.2023.2298358","DOIUrl":"10.1080/14728222.2023.2298358","url":null,"abstract":"Introduction: Mitochondrial LonP1 is an ATP-powered protease that also functions as an ATP-dependent chaperone. LonP1 plays a pivotal role in regulating mitochondrial proteostasis, metabolism and cell stress responses. Cancer cells exploit the functions of LonP1 to combat oncogenic stressors such as hypoxia, proteotoxicity, and oxidative stress, and to reprogram energy metabolism enabling cancer cell proliferation, chemoresistance, and metastasis.Areas covered: LonP1 has emerged as a potential target for anti-cancer therapeutics. We review how cytoprotective functions of LonP1 can be leveraged by cancer cells to support oncogenic growth, proliferation, and survival. We also offer insights into small molecule inhibitors that target LonP1 by two distinct mechanisms: competitive inhibition of its protease activity and allosteric inhibition of its ATPase activity, both of which are crucial for its protease and chaperone functions.Expert opinion: We highlight advantages of identifying specific, high-affinity allosteric inhibitors blocking the ATPase activity of LonP1. The future discovery of such inhibitors has potential application either alone or in conjunction with other anticancer agents, presenting an innovative approach and target for cancer therapeutics.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"9-15"},"PeriodicalIF":5.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10939840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondrial permeability transition pore: a snapshot of a therapeutic target. 线粒体通透性转换孔：治疗靶点快照。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-01-01 Epub Date: 2024-01-19 DOI: 10.1080/14728222.2024.2306337

Mario Zoratti, Lucia Biasutto, Sofia Parrasia, Ildikó Szabo

引用次数: 0

TGF-β as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities. TGF-β 作为梗塞和衰竭心脏的治疗靶点：细胞机制、挑战和机遇。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-01-01 Epub Date: 2024-02-19 DOI: 10.1080/14728222.2024.2316735

Nikolaos G Frangogiannis

{"title":"TGF-β as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities.","authors":"Nikolaos G Frangogiannis","doi":"10.1080/14728222.2024.2316735","DOIUrl":"10.1080/14728222.2024.2316735","url":null,"abstract":"Introduction: Myocardial fibrosis accompanies most cardiac conditions and can be reparative or maladaptive. Transforming Growth Factor (TGF)-β is a potent fibrogenic mediator, involved in repair, remodeling, and fibrosis of the injured heart.Areas covered: This review manuscript discusses the role of TGF-β in heart failure focusing on cellular mechanisms and therapeutic implications. TGF-β is activated in infarcted, remodeling and failing hearts. In addition to its fibrogenic actions, TGF-β has a broad range of effects on cardiomyocytes, immune, and vascular cells that may have both protective and detrimental consequences. TGF-β-mediated effects on macrophages promote anti-inflammatory transition, whereas actions on fibroblasts mediate reparative scar formation and effects on pericytes are involved in maturation of infarct neovessels. On the other hand, TGF-β actions on cardiomyocytes promote adverse remodeling, and prolonged activation of TGF-β signaling in fibroblasts stimulates progression of fibrosis and heart failure.Expert opinion: Understanding of the cell-specific actions of TGF-β is necessary to design therapeutic strategies in patients with myocardial disease. Moreover, to implement therapeutic interventions in the heterogeneous population of heart failure patients, mechanism-driven classification of both HFrEF and HFpEF patients is needed. Heart failure patients with prolonged or overactive fibrogenic TGF-β responses may benefit from cautious TGF-β inhibition.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"45-56"},"PeriodicalIF":5.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting GABA receptors with chalcone derivative compounds, what is the evidence? 用查尔酮衍生物化合物靶向 GABA 受体，证据何在？

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-19 DOI: 10.1080/14728222.2023.2293752

Feba Benny, Sunil Kumar, Aiswarya Binu, Della Grace Thomas Parambi, Tariq G. Alsahli, Abdullah G. Al-Sehemi, Namitha Chandran, Deepthi S. Manisha, Sarath Sreekumar, Akanksha Bhatt, Krishnadas Madhu, Bijo Mathew

引用次数: 0

Novel signatures of prostate cancer progression and therapeutic resistance 前列腺癌进展和耐药性的新特征

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-18 DOI: 10.1080/14728222.2023.2293757

Jason Wang, Reuben Ben-David, Reza Mehrazin, Wei Yang, Ashutosh K. Tewari, Natasha Kyprianou

引用次数: 0

How will the identification and therapeutic intervention of genetic targets in oncology evolve for future therapy? 肿瘤学基因靶点的识别和治疗干预在未来治疗中将如何发展？

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-14 DOI: 10.1080/14728222.2023.2295493

Paolo Baldo, Valli De Re, Mattia Garutti

引用次数: 0

XBP1 as a novel molecular target to attenuate drug resistance in hepatocellular carcinoma XBP1 作为减轻肝细胞癌耐药性的新型分子靶点

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-11 DOI: 10.1080/14728222.2023.2293746

Zahra Hendi, Pedram Asadi Sarabi, David Hay, Massoud Vosough

引用次数: 0

Advances in targeting the extracellular matrix for glaucoma therapy: current updates 针对细胞外基质治疗青光眼的进展：最新进展

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-09 DOI: 10.1080/14728222.2023.2293748

R. Agarwal, I. Iezhitsa

引用次数: 0

Unraveling therapeutic targets in acute myeloid leukemia through multiplexed genome editing CRISPR screening 通过多重基因组编辑 CRISPR 筛选揭示急性髓性白血病的治疗靶点

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-09 DOI: 10.1080/14728222.2023.2293751

Zhen Tian, Stacia Octaviani, Jian Huang

引用次数: 0